Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cord Blood NK Cells with Chemo and Lenalidomide for Hematologic Malignancies
NCT02280525Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2015
- Primary completion
- Jul 2019
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of umbilical cord blood-derived NK cells in chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and 3 more (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 30 days. Started Mar 2015; status: completed.
02
Drugs
umbilical cord blood-derived NK cells
03
Conditions
chronic lymphocytic leukemia (CLL)acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)chronic myeloid leukemia (CML)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT02280525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02280525.